Your browser doesn't support javascript.
loading
Founder mutation in the PMM2 promotor causes hyperinsulinemic hypoglycaemia/polycystic kidney disease (HIPKD).
Islam, Sumaya; Tekman, Mehmet; Flanagan, Sarah E; Guay-Woodford, Lisa; Hussain, Khalid; Ellard, Sian; Kleta, Robert; Bockenhauer, Detlef; Stanescu, Horia; Iancu, Daniela.
Afiliação
  • Islam S; Department Renal Medicine, University College London, London, UK.
  • Tekman M; Department Renal Medicine, University College London, London, UK.
  • Flanagan SE; Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
  • Guay-Woodford L; Center for Translational Research, Children's National Hospital Health System, Washington, DC, USA.
  • Hussain K; Department of Endocrinology, Sidra Medicine, Doha, Qatar.
  • Ellard S; Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK.
  • Kleta R; Department Renal Medicine, University College London, London, UK.
  • Bockenhauer D; Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.
  • Stanescu H; Department Renal Medicine, University College London, London, UK.
  • Iancu D; Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.
Mol Genet Genomic Med ; 9(12): e1674, 2021 12.
Article em En | MEDLINE | ID: mdl-33811480
ABSTRACT

BACKGROUND:

Polycystic kidney disease with hyperinsulinaemic hypoglycaemia (HIPKD) is a recently described disease caused by a single nucleotide variant, c.-167G>T, in the promoter region of PMM2 (encoding phosphomannomutase 2), either in homozygosity or compound heterozygosity with a pathogenic coding variant in trans. All patients identified so far are of European descent, suggesting a possible founder effect.

METHODS:

We generated high density genotyping data from 11 patients from seven unrelated families, and used this information to identify a common haplotype that included the promoter variant. We estimated the age of the promoter mutation with DMLE+ software, using demographic parameters corresponding to the European population.

RESULTS:

All patients shared a 0.312 Mb haplotype which was absent in 503 European controls available in the 1000 Genomes Project. The age of this mutation was estimated as 105-110 generations, indicating its occurrence around 600 BC, a time of intense migration, which might explain the presence of the same mutations in Europeans around the globe.

CONCLUSION:

The shared unique haplotype among seemingly unrelated patients is consistent with a founder effect in Europeans.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regiões Promotoras Genéticas / Fosfotransferases (Fosfomutases) / Efeito Fundador / Hipoglicemia / Doenças Renais Policísticas / Mutação Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: America do norte / Europa Idioma: En Revista: Mol Genet Genomic Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Regiões Promotoras Genéticas / Fosfotransferases (Fosfomutases) / Efeito Fundador / Hipoglicemia / Doenças Renais Policísticas / Mutação Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies Limite: Female / Humans / Male País/Região como assunto: America do norte / Europa Idioma: En Revista: Mol Genet Genomic Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido